Immunomodulation of Hyperthermia for Recurrent Prostate Cancer
Abstract
Currently, there is no curative treatment for recurrent prostate cancer (PC). Although, radiation therapy (RT) has been successful in the treatment of primary PC, it is not used to treat locally recurrent PC because of the high morbidity of pelvic reirradiation. Hyperthermia has undergone extensive study as a treatment for BPH and its safety is very well established. Our long-term goal is to develop hyperthermia as a tumoricidal therapy for recurrent PC. We propose a strategy for in situ tumor vaccination where PC cells release tumor antigens following local treatment with hyperthermia, while cytokine-stimulated dendritic cells (DCs) harvest these antigens to mount an effective tumor-specific immunity in vivo.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2005
- Accession Number
- ADA437721
Entities
People
- Chandan Guha
Organizations
- Montefiore Medical Center